ACCELRYS, INC. 4
4 · ACCELRYS, INC. · Filed Sep 25, 2013
Insider Transaction Report
Form 4
ACCELRYS, INC.ACCL
HAHN MATHEW A
VP, Research and Development
Transactions
- Sale
Common stock
2013-09-23$9.95/sh−15,000$149,289→ 0 total
Footnotes (1)
- [F1]Pursuant to his 10b5-1 plan, Dr. Hahn disposed of common stock acquired through sale of Scitegic to Accelrys in 2004.